Xianjian Technology (01302): G-iliaTM Pro iliac artery stent system obtained official registration approval from China National Drug Administration

Zhitong Finance App News, Xianjian Technology (01302) issued an announcement. On January 7, 2026, the G-iliaTM Pro iliac artery stent system (G-iliaTM Pro or the product) independently developed by the company was officially registered and approved by the China National Drug Administration (China Drug Administration). This product is suitable for intracavitary treatment of abdominal aortic aneurysms combined with iliac aneurysms or isolated common iliac aneurysms. It ensures pelvic blood supply by reconstructing the internal iliac artery, provides a more mature and complete clinical solution, and enables a systematic upgrade of existing treatment plans.

The internal iliac artery is an important branch of the common iliac artery and is responsible for supplying blood to pelvic organs, gluteal muscles, and spinal cord. In early abdominal aortic aneurysm intravitary repair (EVAR), in order to prevent internal leakage, one or both internal iliac arteries are often embolized, causing a series of complications such as gluteal lameness, sexual dysfunction, colon ischemia, rectal necrosis, spinal cord defects, and even paraplegia, which seriously affects the patient's long-term quality of life. Numerous guidelines and consensus at home and abroad have been clarified: during EVAR surgery, at least one side of the internal iliac artery is preserved, so that patients can obtain a good prognosis. Iliac artery branch stenting (IBD) technology has gradually become an ideal choice for intracavitary reconstruction of the internal iliac artery because it is more in line with physiological anatomy, low incidence of internal leakage, and high long-term patency rate.

The G-iliactM iliac artery bifurcation system (formerly known as LifeflowTM iliac artery bifurcation stent system, (G-iliaTM)) was approved and marketed by the State Drug Administration in 2021. It became the first finished IBD device product in China, filling the long-standing market gap in the field of intravenous internal iliac artery reconstruction in China. Its multi-center clinical application and real-world studies have shown that G-iliaTM excels in terms of safety, flow rate, and operational stability, enabling doctors to more calmly complete internal iliac artery reconstruction under complex anatomical conditions.

G-iliaTM Pro consists of the G-iliaCTM Pro laminating stent and the SilverflowTM Pro laminating stent. It is fully upgraded to meet clinical needs on the basis of continuing the G-iliaCTM two-piece combination; long and short main design, which is widely adaptable; multiple entrances to the mountain/brachial artery, providing doctors with more choices; and continuing the SilverflowTM interconnect weave, which is extremely flexible and has a high long-term clearance rate:

Low-profile delivery system: flexible and accessible, providing a better solution for patients with narrow access;

The conveying system design is more ergonomic: user-friendly, precise and controllable release;

The latest hydrophilic coating process: smoother, which is conducive to the smooth introduction of instruments;

Braided sheath tube combined with soft sheath core: optimizes transmission and passability without fear of complicated anatomy;

Clearer mark design: helps accurate positioning during surgery.

The approval for the launch of this product is an important step forward in the Group's mature technology platform. It not only further improves the company's innovative product layout in the field of minimally invasive treatment of the entire aortic cavity, but also provides a better solution for internal iliac artery reconstruction. The Group is also committed to providing the most complete overall solution for minimally invasive aortic treatment, and continuously promoting minimally invasive treatment of complex aortic diseases to a new stage of more systematic, standardized, accurate and efficient development. As the commercialization process continues to advance, the company will continue to work with industry experts to promote the development and marketing of more clinically needed medical device products, drive the Group's development in the medical device field, and benefit patients.